论文部分内容阅读
目的研究乳腺癌组织表皮生长因子受体(EGFR)、癌基因CerbB2和细胞增殖核抗原(PCNA)变化规律,探讨EGFR、CerbB2和PCNA预测乳腺癌复发的价值。方法应用免疫组化检测57例良、恶性乳腺病变组织中EGFR、CerbB2、PCNA的表达,并比较其阳性表达率和程度的差异。结果复发乳腺癌和无复发乳腺癌组织EGFR、CerbB2、PCNA阳性表达率均较乳腺纤维腺瘤组织高,复发乳腺癌PCNA,CerbB2阳性表达程度高于无复发乳腺癌。结论EGFR、CerbB2、PCNA可反映癌组织细胞增殖活跃,PCNA、CerbB2过表达在预测乳腺癌复发和选择治疗方式具有一定价值。
Objective To investigate the changes of epidermal growth factor receptor (EGFR), oncogene CerbB2 and proliferating cell nuclear antigen (PCNA) in breast cancer and to explore the value of EGFR, CerbB2 and PCNA in predicting the recurrence of breast cancer. Methods The expressions of EGFR, CerbB2 and PCNA in 57 cases of benign and malignant breast lesions were detected by immunohistochemistry, and the difference of their positive expression rate and degree was compared. Results The positive rates of EGFR, CerbB2 and PCNA in recurrent breast cancer and non-recurrent breast cancer tissues were higher than those in breast fibroadenoma. The positive expression rates of PCNA and CerbB2 in recurrent breast cancer were higher than those in non-recurrent breast cancer. Conclusion EGFR, CerbB2 and PCNA can reflect the proliferation of cancer cells. The over-expression of PCNA and CerbB2 may be valuable in predicting the recurrence and selection of breast cancer.